EBMT 2023 | FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, gives an update on the ongoing Phase III FORUM trial (NCT01949129). The study compared total body irradiation (TBI) plus etoposide versus myeloablative chemotherapy-based conditioning with fludarabine, thiotepa, and either busulfan or treosulfan in pediatric patients with high-risk acute lymphoblastic leukemia (ALL) prior to allogeneic stem cell transplantation (alloSCT). The study showed that the TBI regimen was superior to chemotherapy-based conditioning in terms of overall survival (OS) and overall patients had very good outcomes post-alloSCT. Prof. Peters explains the the biggest challenge now is relapse, and highlights the significant side effects associated with TBI. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Medac: Honoraria; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Riemser: Consultancy, Speakers Bureau; Jazz: Other, Research Funding; Neovii: Research Funding.
